Autosomal Dominant Polycystic Kidney Disease Clinical Trial
Official title:
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) II
The Division of Kidney Urology and Hematology Disease (DKUHD) of the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) funded a cooperative agreement (UO1) for a
consortium of participating clinical centers (PCCs) and a data coordinating and imaging
analysis center (DCIAC) to develop and implement studies to test whether imaging techniques
can provide accurate and reproducible markers of progression of renal disease in patients
with polycystic kidney disease.
The awarded participating clinical centers are Emory University, University of Kansas, and
Mayo Foundation (with a subcontract to the University of Alabama). The awarded DCIAC is
Washington University in St. Louis. Due to the relocation of the DCIAC P.I. from Washington
University to the University of Pittsburgh, the DCIAC for CRISP II is located at the
University of Pittsburgh.
The goal of the CRISP Study is to conduct a prospective, longitudinal trial to evaluate the accuracy and validity of magnetic resonance imaging to determine disease progression in ADPKD defined as a change in both renal and renal cyst volumes and renal function over time. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02933268 -
High Water Intake in Polycystic Kidney Disease
|
N/A | |
| Completed |
NCT00759369 -
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
N/A | |
| Completed |
NCT00598377 -
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
| Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
| Recruiting |
NCT05193981 -
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
|
||
| Completed |
NCT03487913 -
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
| Not yet recruiting |
NCT06435858 -
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
| Recruiting |
NCT05190744 -
PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
|
Phase 2 | |
| Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
| Recruiting |
NCT04344769 -
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
||
| Active, not recruiting |
NCT02848521 -
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
|
||
| Completed |
NCT01451827 -
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
| Completed |
NCT01210560 -
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
|
Phase 2 | |
| Completed |
NCT01336972 -
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 2 | |
| Completed |
NCT02134899 -
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
|
Phase 3 | |
| Active, not recruiting |
NCT02729662 -
Efficacy of Tolvaptan on ADPKD Patients
|
N/A | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT05288998 -
Intrarenal Microvasculature in ADPKD
|
||
| Recruiting |
NCT04939935 -
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
|
Phase 3 | |
| Withdrawn |
NCT01988038 -
Repository Study of Autosomal Dominant Polycystic Kidney Disease
|
N/A |